CRIS Current Research Information System

MOLLICA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.325
NA - Nord America 3.604
EU - Europa 2.505
SA - Sud America 400
AF - Africa 341
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.508
SG - Singapore 2.234
CN - Cina 2.028
VN - Vietnam 1.462
IT - Italia 708
HK - Hong Kong 532
KR - Corea 400
BR - Brasile 294
DE - Germania 279
SE - Svezia 265
IN - India 236
NL - Olanda 219
GB - Regno Unito 197
FR - Francia 162
FI - Finlandia 144
CH - Svizzera 115
CI - Costa d'Avorio 113
SC - Seychelles 108
RU - Federazione Russa 106
JP - Giappone 98
IE - Irlanda 96
CA - Canada 52
PH - Filippine 47
AR - Argentina 44
ID - Indonesia 44
BG - Bulgaria 43
ZA - Sudafrica 41
BD - Bangladesh 38
PL - Polonia 38
JO - Giordania 33
AT - Austria 31
TH - Thailandia 30
TG - Togo 29
ES - Italia 28
MX - Messico 28
TR - Turchia 27
PK - Pakistan 18
IQ - Iraq 16
TW - Taiwan 14
UA - Ucraina 14
CL - Cile 13
CO - Colombia 11
VE - Venezuela 11
LT - Lituania 10
UZ - Uzbekistan 10
EG - Egitto 9
MY - Malesia 9
NG - Nigeria 9
EC - Ecuador 8
PT - Portogallo 8
SA - Arabia Saudita 8
PE - Perù 7
JM - Giamaica 6
KZ - Kazakistan 6
PY - Paraguay 6
AU - Australia 5
BE - Belgio 5
HR - Croazia 5
HU - Ungheria 5
KE - Kenya 5
RO - Romania 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
GR - Grecia 4
IL - Israele 4
PS - Palestinian Territory 4
TN - Tunisia 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EE - Estonia 3
GH - Ghana 3
IR - Iran 3
NP - Nepal 3
OM - Oman 3
RS - Serbia 3
CD - Congo 2
CY - Cipro 2
ET - Etiopia 2
GT - Guatemala 2
KG - Kirghizistan 2
LB - Libano 2
MA - Marocco 2
ML - Mali 2
SN - Senegal 2
SV - El Salvador 2
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BW - Botswana 1
EU - Europa 1
FJ - Figi 1
GE - Georgia 1
GN - Guinea 1
HN - Honduras 1
IS - Islanda 1
KI - Kiribati 1
KW - Kuwait 1
Totale 14.171
Salva come PNG Salva come JPEG
Città #
Singapore 1.546
Hefei 795
Hong Kong 501
Ashburn 479
Ho Chi Minh City 402
Seoul 376
Hanoi 343
San Jose 287
Santa Clara 237
Beijing 217
Boardman 192
Bologna 168
Chandler 168
Los Angeles 141
Helsinki 115
Abidjan 113
Bern 111
Fairfield 109
Southend 107
Council Bluffs 106
Dublin 95
Milan 84
Dallas 83
Bengaluru 73
Tokyo 73
Lauterbourg 72
New York 61
Princeton 61
Buffalo 60
Da Nang 59
Seattle 56
Redondo Beach 55
Frankfurt am Main 47
Houston 47
Turin 46
Guangzhou 44
Haiphong 43
Sofia 42
Woodbridge 40
Nuremberg 39
Cambridge 38
Wilmington 38
Amman 33
Boydton 33
Shanghai 33
São Paulo 32
Rome 31
Lomé 29
Munich 29
Dong Ket 28
Tongling 28
Jakarta 26
Chicago 25
Johannesburg 25
Ann Arbor 24
Warsaw 24
Florence 23
Lappeenranta 22
Amsterdam 21
London 21
Paris 21
Redmond 20
Vienna 20
Berlin 19
Falkenstein 19
Biên Hòa 18
Denver 17
Montreal 17
Hyderabad 16
Hải Dương 16
Shenzhen 16
Orem 15
Phoenix 15
Can Tho 14
Moscow 14
Stockholm 14
Zhengzhou 14
Des Moines 13
Nanjing 13
Tianjin 13
Toronto 13
Xi'an 13
Atlanta 12
Boston 12
Changsha 12
Quận Bình Thạnh 12
Redwood City 12
Bühl 11
Jinan 11
Bangkok 10
Brooklyn 10
Castel Maggiore 10
Hangzhou 10
Ninh Bình 10
Quận Ba 10
Thái Bình 10
Thái Nguyên 10
Tân Tiến 10
Verona 10
Westminster 10
Totale 8.798
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 265
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 228
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 222
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 215
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 213
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 200
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 197
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 184
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 169
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 160
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 160
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 159
Bone targeting agents in patients with metastatic prostate cancer: State of the art 157
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 157
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 155
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 155
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 155
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 149
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 148
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 147
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 147
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 147
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 145
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 144
The human microbiota and prostate cancer: Friend or foe? 143
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 140
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 139
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 137
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 136
Is There a Role for Immunotherapy in Prostate Cancer? 135
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 134
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 132
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 131
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 129
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 126
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 123
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 121
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 120
The functioning side of the pancreas: a review on insulinomas 119
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 118
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 117
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 117
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 111
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 110
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 109
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 108
Metabolomic profiling in renal cell carcinoma patients: News and views 107
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 106
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 103
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 102
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 102
SOX2 and PRAME in the "reprogramming" of seminoma cells 102
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 101
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 100
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 97
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 96
Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma 95
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 95
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 94
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 92
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 92
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 91
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma 89
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 89
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 88
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 87
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 85
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 84
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 83
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 83
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 81
Treating prostate cancer by antibody-drug conjugates 80
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 80
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 80
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and ‘somatic-type’ adenocarcinoma 79
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 78
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 73
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 73
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 72
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 72
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 71
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 71
Pembrolizumab plus enfortumab vedotin in urothelial cancer 71
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 69
Microbiota and prostate cancer 69
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 69
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 68
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 67
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 67
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 67
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 67
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 67
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 66
Totale 12.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021168 0 0 0 0 0 0 0 0 0 25 11 132
2021/2022533 8 15 16 36 38 22 33 62 65 25 144 69
2022/20231.438 58 99 44 82 132 179 93 94 239 55 158 205
2023/2024753 87 96 64 65 51 100 22 78 40 57 46 47
2024/20253.521 149 429 312 222 417 145 236 159 64 254 406 728
2025/20267.692 909 1.182 904 744 819 305 773 236 1.317 503 0 0
Totale 14.546